

Multidisciplinary care in Parkinson's disease and parkinsonism from science to practice

THE 8TH NATIONAL CONFERENCE

15th July 2003 – Royal College of Physicians, London

This meeting will examine the four phases of management in Parkinson's disease - diagnosis, maintenance, complex and palliative. Topics will include:

- clinical and communication skills that are required to get the diagnosis phase right
- what patients and carers want to know and what the Expert Patient Programme can mean for Parkinson's disease care
- how to manage – or mismanage the complicated drug regimes that characterise the complex stage of PD
- what the issues are in palliative stage and can we do better? What might The National Service Framework for Long Term conditions mean for PD care?

We hope to see you there!

Organised by MEP Ltd on behalf of the BGS PD section meeting

For more information or to register for the conference, please call MEP Ltd on 020 7561 5400 or email info@mepltd.co.uk



Psychosocial Aspects of Epilepsy

15th May 2003
Lingfield, Surrey, UK

The unpredictable nature of seizures has a profound effect on the quality of life for people living with epilepsy. But often it is the psychosocial difficulties that have a greater impact than the seizures themselves. Particular areas of difficulty include education, employment, social and recreational activities, social integration, behavioural and emotional difficulties, independent living and childhood development.

As well as providing a basic understanding of epilepsy, this study day will explore the wider implications of the condition, discussing issues such as the effects of anti-epileptic drugs, behavioural, emotional, psychiatric, and cognitive problems associated with epilepsy. Cost - £80

The Role of EEG in Childhood Epilepsy

17th July 2003
Lingfield, Surrey, UK

EEG has an important role in the diagnosis of epilepsy. However, results need to be carefully interpreted in the context of the clinical data. This course is aimed at Consultants Paediatricians and Paediatricians in training, and aims to highlight the role of EEG in epilepsy management.

Cost - £80

NCYPE, Resource Centre, St Piers Lane, Lingfield, Surrey, RH7 6PW

For further information please contact the Marketing Department on 01342 831 337/237 or email training@ncype.org.uk. Further information and an online booking form is also available from our website at www.ncype.org.uk/resource_centre.htm



The National Centre for Young People with Epilepsy

1st International Symposium on CNS Germ Cell Tumors

Our Symposium welcomes basic researchers, pathologists, radiologists, oncologists, psychologists, neurosurgeons, and anyone involved in clinical activities for CNS germ cell tumor patients. The three major objectives of the Symposium are:

- To demonstrate basic scientific data to facilitate better understanding of the nature of the tumors.
- To demonstrate and evaluate the clinical treatment results.
- To facilitate and enable establishment of standard therapeutic protocols.

September 17-19, 2003
Kyoto, Japan



For further information, please contact the Secretariat at: The First International Symposium on CNS Germ Cell Tumors, c/o Convex Inc., Ichijoji Bldg., 2-3-22 Azabudai, Minato-ku, Tokyo 106-0041, Japan. Tel: +81-3-3589-3355, Fax: +81-3-3589-3974, E-mail: GCTsympo@convex.co.jp, Homepage: <http://www.gctsympo.com/gctsympo/index.html>

Sponsored by: The Japan Brain Foundation; The Pediatric Brain Tumor Foundation of the United States; The Diabetes insipidus Foundation, Inc.; The Japan Society for Neuro-Oncology; The Children's Cancer Association of Japan

BRAIN PLASTICITY & LEARNING BASED THERAPY

July 6-8, 2003 - Villa Gualino Congress Centre, Viale Settimio Severo, 63 - Torino, Italy

The conference aims to bring together scientists working in the field of molecular and cellular mechanisms of synaptic plasticity during development and in the mature brain with those working with rehabilitation strategies.

For on line registration, abstract submission modality, travel grant application modality, accommodation, deadlines, tourist information and more, see www.fobiotech.org/brainrehabilitation

Scientific Committee: Tobias Bonhoeffer, Max Plank Institute for Neurobiology, Munich, D; Lamberto Maffei, Institute of Neurophysiology, CNR, Pisa, I; Michael Merzenich, Keck Center for Integrative Neuroscience, San Francisco, USA; Carla Shatz, Neurobiology Department, Harvard Medical School, Boston USA; Piergiorgio Strata, R. Levi Montalcini Center for Brain Repair, University of Turin, I

Organising Secretariat: Fondazione per le Biotecnologie - contact: Claudia Mondino
Tel. ++ 39 011 6600187, Fax ++ 39 011 6600708, E-Mail: mail@fobiotech.org

International Scientific Conference
co-funded by European Commission
under 5th Framework Programme for
Research & Development



Association of
PHYSIOTHERAPISTS
in PARKINSON'S
Disease EUROPE

A
P
P
D
E



A
E
K
M
P

Association EUROPE des
KINÉSITHÉRAPEUTES
pour la Maladie de
PARKINSON

Association of Physiotherapists in
Parkinson's Disease Europe (APPDE)

1st International Conference Physiotherapy for Parkinson's Disease: Research to Practice

4th July 2003

Chilworth Manor, Southampton, UK

Key note speaker is Professor Meg Morris from Australia, other speakers are from Holland, Belgium and UK

Abstract submissions for poster presentations are invited,
extended deadline May, 9th

For more information contact: Alison Marks, HRRU Secretary, School of Health Professions and Rehabilitation Sciences, University of Southampton, Highfield, Southampton, SO17 1BJ. Tel: 023 8059 4791; Email: adm5@soton.ac.uk, Website: <http://appde.unn.ac.uk>



CNS DRUG TRIALS November 2003 A11-8003

- ◆ Regulatory requirements for CNS drug trials
- ◆ Innovations & developments in trials of new anti-psychotic agents
- ◆ Inter-Rater reliability in CNS clinical studies
- ◆ Brain imaging in drug discovery & development
- ◆ Case studies in CNS drug trials

ALZHEIMER'S DISEASE November 2003 A11-8103

- ◆ Review of current therapies/recent developments
- ◆ AD and pharmacogenetics
- ◆ Dissociating symptom relief from disease modification
- ◆ Cognitive efficacy measurements in AD trials
- ◆ AD Biomarkers 1: Brain Imaging
- ◆ AD Biomarkers 2: CSF, Blood and Plasma Markers

For a full brochure or other information please contact:
Barbara McManus, barbara@management-forum.co.uk
Tel. +44 (0) 1483 570099, Fax. +44 (0) 1483 536424